SCHEMBL16632750

SCHEMBL16632750

COc1cc(Cl)ccc1Oc1cccc2occc12

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.48
SLC6A2 P23975 6/20 0.48
SLC6A3 Q01959 4/20 0.48
KCNH2 Q12809 1/20 0.48
TTR P02766 2/20 0.42
FADS1 O60427 1/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
KCNA3 P22001 1/20 0.39
RHEB Q15382 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16632437 0.82 TTR (0.51) SLC6A2SLC6A3TTRFADS1LMNA
SCHEMBL16632614 0.80 SLC6A4 (0.50) SLC6A4SLC6A2SLC6A3KCNH2TTR
SCHEMBL29761716 0.78 CYP2A6 (0.55) MEN1ALDH1A1KMT2ALMNAHPGD
SCHEMBL827270 0.78 CYP2A6 (0.55) MEN1ALDH1A1KMT2ALMNAHPGD
SCHEMBL16632584 0.78 SLC6A4 (0.48) SLC6A4SLC6A2SLC6A3KCNH2TTR
SCHEMBL29875959 0.77 RHEB (0.52) SLC6A4SLC6A2SLC6A3KCNH2FADS1
SCHEMBL16632723 0.76 SLC6A4 (0.49) SLC6A4SLC6A2SLC6A3KCNH2TTR
SCHEMBL3484014 0.73 KCNA3 (0.40) SLC6A2SLC6A3TTRFADS1MEN1
SCHEMBL676629 0.70 TTR (0.73) SLC6A4SLC6A2SLC6A3KCNH2TTR
Formic Acid SCHEMBL28294284 0.70 CYP2A6 (0.50) MEN1ALDH1A1KMT2ALMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR SLC6A4 4266/4885SLC6A2 3227/4885SLC6A3 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.